King's College London

Research portal

Nuclear Molecular Imaging Strategies in Immune Checkpoint Inhibitor Therapy

Research output: Contribution to journalArticle

Kasper F Guldbrandsen, Helle W Hendel, Seppo W Langer, Barbara M Fischer

Original languageEnglish
Pages (from-to)E23
JournalDiagnostics (Basel, Switzerland)
Volume7
Issue number2
DOIs
Publication statusPublished - 21 Apr 2017

Documents

King's Authors

Abstract

Immune checkpoint inhibitor therapy (ICT) is a new treatment strategy developed for the treatment of cancer. ICT inhibits pathways known to downregulate the innate immune response to cancer cells. These drugs have been shown to be effective in the treatment of a variety of cancers, including metastatic melanoma and lung cancer. Challenges in response evaluation of patients in ICT have risen as immune related side effects and immune cell infiltration may be confused with progressive disease. Furthermore, the timing of the evaluation scan may be challenged by relatively slow responses. To overcome this, new response criteria for evaluating these patients with morphologic imaging have been proposed. The aim of this paper is to review and discuss the current evidence for the use of molecular imaging, e.g., PET/CT (Positron Emission Tomography/Computer Tomography) with (18)F-Fluorodeoxyglucoes (FDG) as an alternative imaging method for monitoring patients undergoing ICT. Following the currently available evidence, this review will primarily focus on patients with malignant melanoma.

Download statistics

No data available

View graph of relations

© 2018 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454